Ipsen, a global biopharmaceutical firm that specializes in neuroscience, oncology and rare diseases, partnered with Exicure, a clinical-stage biotech company that develops treatments for neurological, inflammatory and genetic disorders, to create new therapies for Angelman syndrome (AS) and Huntington’s disease (HD).

Ovid Therapeutics and Angelini Pharma entered into an exclusive license agreement to develop, manufacture and commercialize OV101 for the treatment of Angelman syndrome in Europe.